SCHEMBL16113447

SCHEMBL16113447

CCCOc1ncc(C(=O)O)cc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
MAPT P10636 2/20 0.41
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PLA2G2A P14555 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
RXRA P19793 2/20 0.39
GABRA5 P31644 1/20 0.39
HCAR3 P49019 2/20 0.38
TTR P02766 1/20 0.38
ESR1 P03372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL899216 0.87 MAPT (0.50) KMT2AMEN1POLBHCAR2MAPT
SCHEMBL443075 0.86 HCAR3 (0.43) POLBHCAR2MAPTL3MBTL1CYP2C9
SCHEMBL21078819 0.83 KMT2A (0.46) KMT2AHCAR2MAPTPLA2G2ACYP2C9
SCHEMBL2702914 0.82 PARP1 (0.43) POLBHCAR2PLA2G2AGABRA5TTR
SCHEMBL15662131 0.81 KMT2A (0.45) KMT2APOLBHCAR2MAPTPLA2G2A
SCHEMBL14928310 0.81 KMT2A (0.45) KMT2AHCAR2MAPTRAB9APLA2G2A
SCHEMBL1809302 0.80 TPMT (0.49) KMT2AALDH1A1POLBHCAR2L3MBTL1
SCHEMBL31133274 0.80 TPMT (0.49) KMT2AALDH1A1POLBHCAR2L3MBTL1
SCHEMBL21191122 0.80 NR1H4 (0.46) HCAR2RXRAGABRA5HCAR3
SCHEMBL2121677 0.78 ALDH1A1 (0.51) KMT2AALDH1A1PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC 2025-04-17 US disclosed
US-20230075774-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC (US) 2023-03-09 US disclosed
US-11279691-B2 Substituted pyridine and pyrazine compounds as PDE4 inhibitors DART NEUROSCIENCE LLC (US) 2022-03-22 US disclosed
CN-108299400-B Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors 达特神经科学(开曼)有限公司 2021-02-19 CN disclosed
EP-3345902-B1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2019-10-30 EP disclosed
US-20180346448-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2018-12-06 US disclosed
EP-3345902-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS Dart NeuroScience (Cayman) Ltd (KY) 2018-07-11 EP disclosed
EP-2970212-B1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2018-04-25 EP disclosed
EP-2970212-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS Dart Neuroscience (Cayman) Ltd (KY) 2016-01-20 EP disclosed
US-20160009691-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC 2016-01-14 US disclosed
WO-2014158998-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE, LLC (US) 2014-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180346448-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D KMT2A 1886/4885SMN1; SMN2 409/4885ALDH1A1 1288/4885
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D KMT2A 1886/4885SMN1; SMN2 409/4885ALDH1A1 1288/4885
US-20160009691-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D KMT2A 1912/4885SMN1; SMN2 378/4885ALDH1A1 1356/4885
US-20230075774-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D KMT2A 1886/4885SMN1; SMN2 409/4885ALDH1A1 1288/4885
US-11279691-B2 Substituted pyridine and pyrazine compounds as PDE4 inhibitors PDE4A, PDE4B, PDE4D KMT2A 1912/4885SMN1; SMN2 378/4885ALDH1A1 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.